Diagnostic Performance of FibroScan in a Liver Disease Center in Bogotá from 2019 to 2022
Fuente:
Redalyc
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Asociación Colombiana de Gastroenterologia
2024
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1876462125684097024 |
|---|---|
| author | Diana Torres |
| author_facet | Diana Torres |
| contents | Diagnostic Performance of FibroScan in a Liver Disease Center in Bogotá from 2019 to 2022 Diana Torres Benedicto Velasco Jonathan Alexánder Guezguan-Pérez Medicina FIB APRI FibroScan ROC curves Elastography Introduction: The medical record and liver biochemical profile are essential in diagnosing liver diseases. Liver biopsy is the reference parameter for diagnosis, activity evaluation, fibrosis status, or therapeutic response, but it is invasive and carries risks. For fibrosis staging, easily accessible non-invasive tests without resorting to biopsy have been developed. The FIB-4 and APRI indexes are helpful but do not determine the degree of fibrosis in the early and intermediate stages. Fibrosis can be evaluated using elastography, a sensitive technique to differentiate patients without fibrosis from those with advanced fibrosis. Objective: To describe the diagnostic performance of FibroScan in detecting fibrosis compared to the APRI and FIB-4 indexes versus the biopsy in a care center for patients with liver diseases in Bogotá. Methods: A retrospective, cross-sectional cohort study compared the APRI, FIB-4, and Fibroscan with biopsy; diagnostic accuracy measures and an area under the curve (AUROC) analysis were described. Results: The biopsy was positive for fibrosis in 40%. The AUROC was 0.90 (confidence interval CI: 0.83-0.97) for FibroScan, 0.52 (CI: 0.35-0.68) for APRI, and 0.52 (CI: 0.37-0.68) for FIB-4. Conclusions: FibroScan helps diagnose and monitor chronic liver disease and should be combined with other tests and the clinical picture. FibroScan was better at detecting advanced stages when discriminating against patients with liver fibrosis than the APRI and FIB-4 indexes. 2024 artículo científico 0120-9957 https://www.redalyc.org/articulo.oa?id=337782277005 https://www.redalyc.org/journal/3377/337782277005/ https://www.redalyc.org/journal/3377/337782277005/html/ https://www.redalyc.org/journal/3377/337782277005/337782277005.epub https://www.redalyc.org/journal/3377/337782277005/movil 10.22516/25007440.1097 en http://www.redalyc.org/revista.oa?id=3377 Revista Colombiana de Gastroenterología application/pdf Asociación Colombiana de Gastroenterologia Revista Colombiana de Gastroenterología (Colombia) Num.1 Vol.39 |
| format | Artículo científico |
| id | redalyc_337782277005 |
| institution | Redalyc |
| language | en |
| publishDate | 2024 |
| publisher | Asociación Colombiana de Gastroenterologia |
| spellingShingle | Diagnostic Performance of FibroScan in a Liver Disease Center in Bogotá from 2019 to 2022 Diana Torres Medicina FIB APRI FibroScan ROC curves Elastography Diagnostic Performance of FibroScan in a Liver Disease Center in Bogotá from 2019 to 2022 Diana Torres Benedicto Velasco Jonathan Alexánder Guezguan-Pérez Medicina FIB APRI FibroScan ROC curves Elastography Introduction: The medical record and liver biochemical profile are essential in diagnosing liver diseases. Liver biopsy is the reference parameter for diagnosis, activity evaluation, fibrosis status, or therapeutic response, but it is invasive and carries risks. For fibrosis staging, easily accessible non-invasive tests without resorting to biopsy have been developed. The FIB-4 and APRI indexes are helpful but do not determine the degree of fibrosis in the early and intermediate stages. Fibrosis can be evaluated using elastography, a sensitive technique to differentiate patients without fibrosis from those with advanced fibrosis. Objective: To describe the diagnostic performance of FibroScan in detecting fibrosis compared to the APRI and FIB-4 indexes versus the biopsy in a care center for patients with liver diseases in Bogotá. Methods: A retrospective, cross-sectional cohort study compared the APRI, FIB-4, and Fibroscan with biopsy; diagnostic accuracy measures and an area under the curve (AUROC) analysis were described. Results: The biopsy was positive for fibrosis in 40%. The AUROC was 0.90 (confidence interval CI: 0.83-0.97) for FibroScan, 0.52 (CI: 0.35-0.68) for APRI, and 0.52 (CI: 0.37-0.68) for FIB-4. Conclusions: FibroScan helps diagnose and monitor chronic liver disease and should be combined with other tests and the clinical picture. FibroScan was better at detecting advanced stages when discriminating against patients with liver fibrosis than the APRI and FIB-4 indexes. 2024 artículo científico 0120-9957 https://www.redalyc.org/articulo.oa?id=337782277005 https://www.redalyc.org/journal/3377/337782277005/ https://www.redalyc.org/journal/3377/337782277005/html/ https://www.redalyc.org/journal/3377/337782277005/337782277005.epub https://www.redalyc.org/journal/3377/337782277005/movil 10.22516/25007440.1097 en http://www.redalyc.org/revista.oa?id=3377 Revista Colombiana de Gastroenterología application/pdf Asociación Colombiana de Gastroenterologia Revista Colombiana de Gastroenterología (Colombia) Num.1 Vol.39 |
| title | Diagnostic Performance of FibroScan in a Liver Disease Center in Bogotá from 2019 to 2022 |
| topic | Medicina FIB APRI FibroScan ROC curves Elastography |
| url | https://www.redalyc.org/articulo.oa?id=337782277005 https://www.redalyc.org/journal/3377/337782277005/ https://www.redalyc.org/journal/3377/337782277005/html/ https://www.redalyc.org/journal/3377/337782277005/337782277005.epub https://www.redalyc.org/journal/3377/337782277005/movil |